IngredientsGlucoamylase (GA), also known as amyloglucosidase or γ-amylase (EC 3.2.1.3), is a biocatalyst capable of hydrolyzing α-1,4 glycosidic linkages in raw (sparsely soluble) or soluble starches and related oligosaccharides with the inversion of the anomeric configuration to produce β-glucose. Glucoamylase enzymes (glucan 1,4-α-glucohydrolases, EC 3.2.1.3) are starch hydrolyzing exo-acting carbohydrases, which catalyze the removal of successive glucose units from the non-reducing ends of starch or related oligo and polysaccharide molecules.
Glucoamylases can hydrolyze both the linear and branched glucosidic linkages of starch (e.g., amylose and amylopectin). This distinguishes glucoamylase from the closely related alpha-amylase, which is an endo-acting enzyme that cleaves internal glycosidic bonds. Alpha-glucosidase and glucoamylase are essentially distinguished by releasing alpha-glucose and beta-glucose, respectively, from the common substrates having alpha-glucosidic linkage.
The majority of glucoamylases are multidomain enzymes consisting of a catalytic domain connected to a starch-binding domain by an O-glycosylated linker region. The catalytic domain folds as a twisted (α/α)6-barrel with a central funnel-shaped active site, while the starch-binding domain folds as an antiparallel β-barrel and has two binding sites for starch or β-cyclodextrin.
The "FCC" designation, frequently seen on supplement labels, indicates that the enzyme meets the purity and quality standards set by the Food Chemicals Codex.
Glucoamylases are produced by numerous strains of bacteria, fungi, yeast and plants. Particularly interesting, and commercially important, glucoamylases are fungal enzymes that are extracellularly produced, for example from strains of Aspergillus.
There are two main types of glucoamylase used in the food industry: microbial and plant-based. Microbial glucoamylase is commonly derived from fungi such as Aspergillus niger, while plant-based glucoamylase can be sourced from sweet potatoes and other starchy vegetables. For dietary supplement applications, glucoamylase is isolated from Aspergillus niger, Aspergillus oryzae, Rhizopus niveus, and Rhizopus oryzae.
Three-dimensional structures have been determined of free and inhibitor complexed glucoamylases from Aspergillus awamori var. X100, Aspergillus niger, and Saccharomycopsis fibuligera. Fungi are employed to produce industrially important glucoamylases. Most glucoamylases are glycosylated, and glycosylation enhances enzyme stability.
In traditional East Asian fermentation, the koji mold Aspergillus oryzae expresses three amylase genes, including α-amylase and glucoamylase, which are essential for starch hydrolysis and glucose production. These enzymes display high thermal stability, with α-amylase remaining active up to 75 °C and glucoamylase showing optimal activity at around 60 °C.
Optimal activity is observed at pH 4.5 to 6.5 and 50 to 70 °C. The enzyme activity is measured in Amyloglucosidase Units/g (AGU/g); the food enzyme has a temperature optimum around 70 °C (at pH 5.0) and a pH optimum around 4.0 (at T = 37 °C). The glucan 1,4-α-glucosidase activity decreases rapidly above 60 °C and shows no residual activity above 80 °C.
Glucoamylase itself was not isolated as a defined entity in traditional practice; rather, it was the active enzymatic principle produced by koji and related mold cultures that underpinned millennia of East Asian starch-fermenting traditions. The enzyme was functionally exploited long before its biochemical identity was understood.
Aspergillus oryzae, also known as kōji mold, is a mold used in East Asia to saccharify rice, sweet potato, and barley in the making of alcoholic beverages such as sake and shōchū, and also to ferment soybeans for making soy sauce and miso. The technique of solid-state cultivation using rice grains, soybeans, and wheat bran to propagate fungi for use in fermented foods is believed to have originated in China.
During shochu production, koji fungi play a critical role in the conversion of starches contained in primary ingredients (e.g., rice, barley, buckwheat, and sweet potato) to glucose, which Saccharomyces cerevisiae utilizes to produce ethanol. Black and white koji fungi produce glucoamylase (GlaA), an exo-type enzyme that hydrolyzes α-glycosidic linkages in starch and dextrin, and also exhibits high tolerance to the low pH of shochu mash.
Beyond Japan, glucoamylase-producing organisms were central to fermentation traditions throughout Asia. For decades, Loog-pang-khao-mak has been used as a traditional fermentation starter of fermented Thai food and beverage products such as Kao-mak (sweet fermented glutinous rice), Num Som Saichu (rice vinegar), and Satoh (rice wine). This kind of traditional starter has also been used in various other Asian countries with native names such as Nuruk in Korea, Ragi in Indonesia, Murcha in India, Bubod in the Philippines, Fen-daqu in China, Ragi-tapai in Malaysia, and Koji in Japan.
Fungi exhibiting high glucoamylase activity identified from Loog-pang-khao-mak include Aspergillus niger, Aspergillus oryzae, and Amylomyces rouxii. A. rouxii has been used for centuries as a culture starter for production of traditional fermented food and alcoholic beverages in East Asian countries, while Aspergillus oryzae and A. niger have also been isolated from traditional fermentation starters in various Asian countries such as Loog-pang-khao-mak in Thailand, Hong qu and Yao qu in China, Koji in Japan, and Nuruk in Korea.
Although not used medicinally under the name "glucoamylase," fermented starch preparations were widely employed across these cultures for purposes beyond alcohol production — including food preservation, flavour enhancement, and as general digestive aids in traditional food practice. The enzyme was a functional, if unnamed, participant in all of these preparations.
As an enzyme, glucoamylase is itself the active constituent rather than a crude botanical containing multiple phytochemicals. Its relevant chemical characteristics are structural and catalytic.
The majority of glucoamylases are multidomain enzymes consisting of a catalytic domain connected to a starch-binding domain by an O-glycosylated linker region. Glucoamylases contain both starch binding and catalytic binding domains, the former being responsible for activity on raw (insoluble) starch. Proteases may act on this domain causing the enzyme to lose its activity on insoluble starch.
The subunit molecular mass estimated by SDS–PAGE for A. niger glucoamylase is 93 kDa, while the molecular mass determined by MALDI-TOF is approximately 72–73 kDa. Glucoamylases contain up to 7 sub-sites with highly varying affinity. Most glucoamylases are glycosylated, and glycosylation enhances enzyme stability.
Glucoamylases (GAs) are exo-acting enzymes that catalyse the hydrolysis of α-1,4 and α-1,6 glucosidic linkages from the non-reducing ends of starch and related oligo- and polysaccharides into short-chain saccharides.
The widely accepted mechanism of hydrolysis involves proton transfer from the catalyst to the glycosidic oxygen of the scissile bond. A general acid–base catalyst donates hydrogen to the glucosidic oxygen and a catalytic base guides the nucleophilic attack by a water molecule on the C-1 carbon of the glucose moiety. The amino acid residue Glu 179 of glucoamylase produced by Aspergillus niger has been identified as the general acid catalyst, and Glu 400 as the probable catalytic base group.
The hydrolysis of glucosidic linkage catalyzed by every carbohydrate-hydrolase is a reaction in which the product retains or inverts the anomeric configuration of the substrate. Alpha-glucosidase and glucoamylase are essentially distinguished by releasing alpha-glucose and beta-glucose, respectively, from the common substrates having alpha-glucosidic linkage.
The enzyme acts locally within the gastrointestinal tract, specifically in the lumen, to facilitate the breakdown of dietary starch. It does not get absorbed systemically into the bloodstream but rather performs its catalytic function directly on the food components. Its primary molecular targets are starch polymers and maltose, converting them into absorbable glucose, thereby aiding the digestive process and potentially increasing nutrient availability from carbohydrate-rich foods.
It is important to distinguish the exogenous (supplemental or microbial) glucoamylase discussed in this article from the endogenous mucosal enzyme maltase-glucoamylase (MGAM). Six enzyme activities — two α-amylases and four mucosal α-glucosidases (maltases), including maltase-glucoamylase (Mgam) and sucrase-isomaltase (Si) subunit activities — are needed to digest starch to absorbable free glucose. Exogenous supplemental glucoamylase is intended to supplement or complement this endogenous system.
The most fundamental and well-established function of glucoamylase is the hydrolysis of starch to glucose, a property that has been extensively characterized biochemically. Glucoamylase enhances the digestibility of starches, making nutrients more bioavailable.
In vitro evidence: Glucoamylase has been extensively studied in industrial and animal applications; however, human clinical research on its efficacy as a supplement is less robust, with most evidence derived from in vitro studies, animal models, and enzyme characterization.
Animal evidence: Sucrase deficiency in a model of congenital sucrase-isomaltase deficiency reduces blood glucose response to starch feeding. Supplementing the diet with oral recombinant glucoamylase significantly improved starch digestion in the sucrase-deficient shrew.
Human clinical evidence: Direct, isolated, single-enzyme human clinical trials on glucoamylase are sparse. Most human evidence derives from multi-enzyme blend studies in which glucoamylase is one of several active components, limiting attribution of effects to glucoamylase alone. While glucoamylase effectively breaks down starch into glucose, direct clinical evidence demonstrating significant digestive improvement in humans is limited.
A 2024 randomized, double-blind, placebo-controlled exploratory study (published in Frontiers in Nutrition, PMC11292951) examined the enzyme blend Elevase® — which included glucoamylase among 13 enzymes — in individuals with ileostomies, allowing direct measurement of macromolecule breakdown in ileal effluent. The study was conducted as a randomized, crossover, placebo-controlled design where each participant served as their own control. This post-hoc analysis investigated the impact of a dietary enzyme supplementation blend on dietary macromolecule digestion in samples from otherwise healthy participants that had previously undergone a small bowel resection, resulting in an ileostomy. This is the first time this study-paradigm has been used for the assessment of in vivo dietary breakdown following enzyme supplementation. The multi-enzyme nature of the tested blend means findings cannot be attributed specifically to glucoamylase.
A 2025 PubMed-indexed randomized, double-blind, placebo-controlled crossover trial (PMID 41662956) examined a 6-enzyme preparation including glucoamylase and amylase in 30 middle-aged and older adults. The objective was to assess postprandial plasma nutrient concentrations after co-ingestion of a mixed meal and a mixture of 6 enzyme preparations including proteases, lipase, amylase, and glucoamylase. Thirty middle-aged and older adults (56 ± 11 years; 18 females, 12 males) ingested chicken, peas, potatoes, and butter (435 kcal; 34 g protein, 51 g carbohydrate, 11 g fat) with either the enzyme blend or placebo in a randomized crossover fashion. Blood samples were collected at baseline and throughout a 0–5 h postprandial period for measurement of plasma amino acid, insulin, glucose, and nonesterified fatty acid (NEFA) concentrations. Again, the multi-enzyme formulation prevents isolating glucoamylase's individual contribution.
Evidence strength: Moderate for the enzyme class in combination; insufficient for isolated glucoamylase in humans.
Post-prandial gastrointestinal symptoms such as diarrhea, abdominal distension, flatulence, bloating, and a feeling of fullness are common complaints of often unknown etiology and pathogenesis. There is a long history of trials reporting the successful use of products containing a variety of combinations of digestive enzymes including a number of randomized placebo-controlled trials.
A randomized, double-blind, placebo-controlled study published in Journal of Medicinal Food (2018) evaluated a multi-enzyme complex (MEC) containing α-amylase, protease, cellulase, lactase, and lipase (not explicitly identifying glucoamylase as an isolate) in patients with functional dyspepsia. Supplementation with MEC was associated with statistically significant differences (P value ranging from .0401 to .0033) in all efficacy parameters compared with placebo. The between-group comparison also revealed that MEC supplement had a significantly greater effect (P < .001) versus placebo. No investigation product-related adverse events were reported. There were no clinically significant abnormalities in physical findings and no statistically significant changes in biochemical and hematological parameters, vital signs, body weight, or body mass index between the two groups at baseline and follow-up visits. MEC supplementation represents an effective and safe alternative to manage dyspepsia symptoms in FD patients.
A 2023 randomized, double-blind, placebo-controlled monocentric clinical trial (published in Biomedicine & Pharmacotherapy) further evaluated a multi-enzyme blend from fungal fermentation. The study assessed the effectiveness and tolerability of the supplementation of a normal diet with a multi-enzyme blend obtained from fungal fermentation. Enrolled subjects (n = 120, male: 63, female: 57), aged 18–59 years, were randomized (allocation ratio 1:1) to receive either 2 capsules per day of the food supplement (containing 200 mg of the multi-enzyme blend/capsule) or placebo, for 2 months.
A narrative review published in PMC (PMC6910206) covering 60 years of enzyme trials concluded: A narrative review of studies describing the use of multi-digestive enzymes for symptoms consistent with irritable bowel syndrome describes clinical trials reported over the past 60 years including double-blinded randomized, placebo-controlled studies and recent trials that focused on post-prandial diarrhea consistent with diarrhea-predominant irritable bowel syndrome.
Evidence strength: The body of evidence for multi-enzyme blends (including glucoamylase) in functional dyspepsia and post-prandial GI symptoms is moderate based on several RCTs. However, clinical trials isolating glucoamylase's contribution are absent, and the overall evidence base requires larger, more rigorously designed trials.
Glucoamylase is mechanistically implicated in blood glucose dynamics because its product — free glucose — is the substrate for intestinal absorption. Enzymes including glucoamylase, sucrase, maltase, and isomaltase are the targets of alpha-glucosidase inhibitor drugs; by delaying carbohydrate absorption, they reduce the rise in postprandial blood glucose concentrations by about 3 mmol/L. Notably, acarbose (the pharmaceutical alpha-glucosidase inhibitor) is most effective against glucoamylase. This relationship is pharmacologically relevant: glucoamylase inhibition, rather than supplementation, is the therapeutic strategy in diabetes management.
As a supplemental enzyme aimed at enhancing digestion, glucoamylase's net effect on postprandial glycemia in healthy individuals has not been well studied in isolation. The acceleration of starch breakdown could theoretically increase the glycemic index of a meal, though this has not been established in dedicated human studies.
Evidence strength: Mechanistic evidence is strong; dedicated human clinical evidence for glucoamylase supplementation effects on blood glucose in either healthy or diabetic populations is insufficient.
Age-related decline in digestive function increases malnutrition risk. Supplementing meals with digestive enzymes may improve macronutrient digestion and bioavailability in adults reaching older ages. The 2025 randomized crossover trial described in Section 5.1 was specifically conducted in middle-aged and older adults (mean age 56 ± 11 years), investigating whether enzyme blends including glucoamylase could address this age-related gap. Outcomes measured included postprandial plasma amino acids, insulin, glucose, and NEFA concentrations. Results have been published but attributing specific effects to glucoamylase within the multi-enzyme formulation is not possible from the study design.
Evidence strength: Rationale is scientifically coherent; direct human evidence isolating glucoamylase's role in age-related digestive support is absent.
The most rigorous controlled evidence for glucoamylase as a standalone supplement comes from animal studies. Enzyme supplementation, regardless of enzyme type, increased apparent total tract digestibility of dry matter (from 66.7% to 73.1% ± 2.01), and starch (from 74.7% to 81.8% ± 2.25). Dietary glucoamylase supplementation improved 7 to 13% apparent digestibility of dry matter and starch in bulls fed rolled corn-based diets, suggesting that enzyme (glucoamylase) supplementation could be a promising strategy to improve starch efficiency for finishing beef cattle.
Supplementation with amylase combined with glucoamylase or protease showed a beneficial effect on starch digestibility and intestinal microbiota diversity, and increased growth of broilers fed with newly harvested corn. Supplementation of enzymes changed cecal microbiota diversity; high numbers of Campylobacter, Helicobacter and Butyricicoccus, Anaerostipes and Bifidobacterium, Sutterella and Odoribacter were the main genera detected in supplemented groups.
These animal findings cannot be directly extrapolated to human supplementation; they demonstrate enzymatic efficacy but in fundamentally different digestive systems and diets.
Glucoamylase is available as enzyme concentrates or often combined with other digestive enzymes like alpha-amylase and proteases in multi-enzyme formulations. The "FCC" designation indicates that the enzyme meets the purity and quality standards set by the Food Chemicals Codex.
Enzyme activity for glucoamylase is expressed in Amyloglucosidase Units (AGU), reflecting the enzyme's rate of starch hydrolysis rather than a simple mass measurement. The in-house determination of glucoamylase activity is based on hydrolysis of maltose and is expressed in Amyloglucosidase Units/g (AGU/g) (reaction conditions: pH = 4.3, T = 37°C, incubation time 6 min).
In dietary supplement applications where glucoamylase is isolated from Aspergillus niger, one patent-described enzyme formulation specifies a dosage that should not exceed 300 AGU per day.
In a 2023 RCT in functional dyspepsia, subjects received either 2 capsules per day of the food supplement (containing 200 mg of the multi-enzyme blend/capsule) or placebo, for 2 months; the exact glucoamylase activity within the blend was not separately reported.
Specific minimum effective doses or optimal dosage ranges for human supplementation of glucoamylase have not been definitively established through clinical trials. Industrial and animal studies utilize dosages based on enzyme activity units, which are not directly standardized for human use. For optimal effect, supplemental glucoamylase should be taken with meals that contain starch, as its action is directly on dietary carbohydrates during digestion.
Glucoamylase is generally recognized as safe (GRAS) based on its long history of use in food processing and comprehensive toxicology studies, which have shown no genotoxicity or toxicity.
The FDA has received and acknowledged multiple GRAS notifications for glucoamylase produced from Aspergillus niger-based strains. Aspergillus niger has a long history of safe use; the FDA has previously affirmed as GRAS several enzyme preparations from Aspergillus niger. Aspergillus niger has been used by industry since 1919 for the production of citric acid, and the FDA has listed Aspergillus niger as a source of citric acid in 21 CFR 173.280.
The European Food Safety Authority (EFSA) has published dedicated safety evaluations of glucoamylase preparations. In its 2018 assessment of glucoamylase from genetically modified Aspergillus niger (strain NZYM-BF) by Novozymes A/S, EFSA concluded: The food enzyme glucoamylase (glucan 1,4-α-glucosidase; EC 3.2.1.3) is produced with the genetically modified strain of Aspergillus niger by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This glucoamylase is intended to be used in brewing processes and in starch processing for glucose syrups production. Genotoxicity tests did not raise a safety concern.
Similarly, EFSA's 2020 assessment of glucoamylase from genetically modified Trichoderma reesei (strain DP-Nzh38) concluded: Toxicity studies carried out with another glucoamylase from T. reesei were considered suitable. Genotoxicity tests did not raise safety concerns.
A significant and well-documented safety concern for glucoamylase pertains to occupational inhalation exposure, particularly in the baking industry. In recent years, a decline in the rate of sensitizations to α-amylase (Aspergillus oryzae) has been observed in bakers undergoing occupational medical examination for allergic obstructive airway disease. At the same time, glucoamylase (amyloglucosidase, Aspergillus niger) was identified as the current most significant allergen in sensitization to enzymes used in the baking industry. The high sensitization rate to glucoamylase in affected bakers gives cause to investigate exposure levels in bakeries and to assess sensitizations in the context of occupational disease proceedings.
Formally, the matching allergen for A. niger glucoamylase is Sch c 1, a glucoamylase from Schizophyllum commune, an enzyme described as an occupational respiratory allergen associated with baker's asthma. No information is available on oral sensitisation or elicitation reactions of this glucoamylase.
Critically, the distinction between inhalation sensitization (occupational) and oral exposure (supplemental) is important: several studies have shown that adults with occupational asthma caused by an enzyme can ingest respiratory allergens without acquiring clinical symptoms of food allergy. Nevertheless, individuals with known mold allergies (particularly to Aspergillus species) should be aware that commercially available glucoamylase supplements are predominantly produced from Aspergillus niger.
The enzyme acts locally in the gut, and its efficacy can be influenced by its stability under gastric conditions, though this is generally robust for fungal-derived enzymes. In the multi-enzyme RCTs reviewed, adverse event profiles were generally benign. No investigation product-related adverse events were reported in one functional dyspepsia RCT, and there were no clinically significant abnormalities in physical findings or statistically significant changes in biochemical and hematological parameters, vital signs, body weight, or BMI.
Because pharmaceutical alpha-glucosidase inhibitors (such as acarbose, miglitol, and voglibose) exert their anti-diabetic effects precisely by blocking glucoamylase activity, there is a logical pharmacodynamic interaction: acarbose is most effective against glucoamylase. Co-administration of supplemental glucoamylase with acarbose could theoretically counteract the drug's mechanism of action, reducing postprandial glucose control. No clinical studies have directly investigated this interaction; it is inferred from the established pharmacology of the drug class.
Because glucoamylase's enzymatic action converts starch to free glucose, high-dose supplementation with starchy meals could in principle accelerate glucose absorption and raise the glycemic response of a meal. This consideration has not been rigorously studied in humans but is mechanistically plausible. It may be particularly relevant for individuals with glucose metabolism disorders or those monitoring glycemic index.
Commercial glucoamylase for dietary supplements is predominantly derived from Aspergillus niger. The glucoamylase enzyme preparation meets appropriate food-grade specifications and is produced in accordance with current good manufacturing practices, making it GRAS for the intended conditions of use. Regulatory requirements across the US (FDA GRAS) and Europe (EFSA safety opinions) mandate that the food enzyme preparations be free from viable cells of the production organism and from recombinant DNA where applicable.
Health conditions that Glucoamylase may help support.
Inadequate starch digestion due to reduced glucoamylase activity allows oligosaccharides to reach the colon, where bacterial fermentation produces gas, bloating, and cramping. Clinical trials of multi-enzyme blends containing glucoamylase have demonstrated significant reductions in post-meal abdominal distension and discomfort.
Glucoamylase is the rate-limiting enzyme in the conversion of dietary starch oligomers to free glucose at the intestinal brush border, making it a direct determinant of the pace and magnitude of postprandial blood glucose rise. Animal studies confirm that loss of this enzymatic step significantly elevates postprandial glycemia.
Glucoamylase (amyloglucosidase) cleaves glucose units from the non-reducing ends of starch and dextrins. It is produced in the small intestinal brush border and is included in broad-spectrum digestive enzyme formulations for carbohydrate digestion support. It complements amylase activity by completing starch hydrolysis to absorbable glucose.
Glucoamylase catalyzes the release of free glucose from oligosaccharides, directly enabling cellular uptake of the body's primary energy substrate. Without adequate glucoamylase activity, starch-derived glucose cannot be fully liberated for absorption and metabolic use.
Reduced or absent MGAM activity leads to incomplete starch digestion, generating symptoms (bloating, gas, diarrhea, cramping) that closely mimic carbohydrate food sensitivities. Genetic studies have linked MGAM variants to symptomatic carbohydrate maldigestion, and enzyme supplementation may reduce these reactions.
The efficiency of small intestinal starch digestion by glucoamylase directly determines the quantity and type of carbohydrate substrate reaching the colon, which in turn shapes the composition and metabolic output of the gut microbiome. Insufficient glucoamylase activity increases colonic starch fermentation and may alter microbial community structure.
Rare deleterious variants in the MGAM gene have been identified as candidate contributors to IBS susceptibility, linking glucoamylase deficiency to IBS-like carbohydrate malabsorption symptoms. Multi-enzyme blends including glucoamylase have improved GI symptoms in IBS patients in clinical trials.
Clinical evidence from a trial in hospitalized patients found that enzyme preparations containing glucoamylase improved symptoms including nausea and vomiting. These effects are attributed to improved overall upper GI digestive function rather than a direct anti-emetic mechanism.
Body systems that Glucoamylase may help support.
Go back